Adipokine update - New molecules, new functions

被引:16
|
作者
Gelsinger C. [1 ]
Tschoner A. [1 ]
Kaser S. [1 ]
Ebenbichler C.F. [1 ]
机构
[1] Universitätsklinik für Innere Medizin I, Department Innere Medizin, Medizinische Universität Innsbruck, 6020 Innsbruck Österreich
关键词
Adipokines; Diabetes; Inflammatory disease; Insulin resistance; Metabolic syndrome; Obesity; Visceral adipose tissue;
D O I
10.1007/s10354-010-0781-6
中图分类号
学科分类号
摘要
The prevalence of obesity is rising worldwide. Recent research findings show that adipose tissue is a highly active endocrine organ, which is involved in many physiological processes. These metabolic processes are influenced by products of the adipose tissue, so-called adipokines, which play a crucial role in the pathogenesis of the metabolic syndrome and cardiovascular disease. In addition, the two major fat depots - intraabdominal and subcutaneous - differ in their ability to secrete adipokines. In recent years the importance of the association between intraabdominal fat and the development of insulin resistance, diabetes mellitus type 2 and dyslipidemia was recognized. Therefore, accumulation of visceral adipose tissue contributes due to its ability to secrete a different pattern of adipokines to increased morbidity and mortality. This review aims to characterize novel, newly recognized adipokines and to discuss their roles in the pathogenesis of insulin resistance and atherosclerosis, as well as other metabolic complications. © Springer-Verlag 2010.
引用
收藏
页码:377 / 390
页数:13
相关论文
共 50 条
  • [31] Vascular disease and dementias: Paradigm shifts to drive research in new directions
    Kling, Mitchel A.
    Trojanowski, John Q.
    Wolk, David A.
    Lee, Virginia M. Y.
    Arnold, Steven E.
    ALZHEIMERS & DEMENTIA, 2013, 9 (01) : 76 - 92
  • [32] Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA
    Stejskal, David
    Sigutova, Radka
    Svestak, Marek
    Vaclavik, Jan
    Kusnierova, Pavlina
    Svagera, Zdenek
    BIOMEDICAL PAPERS-OLOMOUC, 2020, 164 (02): : 138 - 140
  • [33] SPECIALTY UPDATE What's New in Foot and Ankle Surgery
    Lin, Sheldon S.
    Yeranosian, Michael G.
    Bastian, Sevag A.
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2017, 99 (08) : 700 - 706
  • [34] Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials
    Haffner, SM
    Ruilope, L
    Dahlöf, B
    Abadie, E
    Kupfer, S
    Zannad, F
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 (03) : 469 - 475
  • [35] Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases
    Scholz, Gerhard H.
    Hanefeld, Markolf
    VISCERAL MEDICINE, 2016, 32 (05) : 319 - 326
  • [36] Perihepatic Adipose Tissue Thickness: a New Non-Invasive Marker of NAFLD?
    Lirussi, Flavio
    Vitturi, Nicola
    Azzalini, Lorenzo
    Orando, Serena
    Orlando, Rocco
    Plebani, Mario
    Realdi, Giuseppe
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (01) : 61 - 66
  • [37] Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver
    Sung, Ki-Chul
    Ryu, Seungho
    Lee, Jong-Young
    Kim, Jang-Young
    Wild, Sarah H.
    Byrne, Christopher D.
    JOURNAL OF HEPATOLOGY, 2016, 65 (04) : 791 - 797
  • [38] Evaluation of concentrations of FGF-21-a new adipocytokine in type 2 diabetes
    Matuszek, Beata
    Lenart-Lipinska, Monika
    Duma, Dariusz
    Solski, Janusz
    Nowakowski, Andrzej
    ENDOKRYNOLOGIA POLSKA, 2010, 61 (01) : 50 - 54
  • [39] Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities
    Kanwal, Abhinav
    Kanwar, Navjot
    Bharati, Sanjay
    Srivastava, Prateek
    Singh, Shailendra P.
    Amar, Salomon
    BIOMEDICINES, 2022, 10 (02)
  • [40] Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers?
    Bergmann, Katarzyna
    Sypniewska, Grazyna
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (01) : 177 - 185